SB-623 is a gene-modified cell therapy commercialized by SanBio, with a leading Phase II program in Traumatic Brain Injury. According to Globaldata, it is involved in 6 clinical trials, of which 3 were completed, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of SB-623’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for SB-623 is expected to reach an annual total of $18 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
SB-623 is under development for the treatment of chronic motor deficit from ischemic stroke and traumatic brain injury, Parkinson's disease (PD), dry age related macular degeneration, retinitis pigmentosa, spinal cord injury, Alzheimer's disease and hemorrhagic stroke. It is administered through parenteral and intracerebral route as an implant. SB-623 is a stem cell therapy product produced by gene transfer of Notch-1 into MSCs isolated from bone marrow fluid obtained from healthy adult donors. The drug candidate is based on regenerative technology. It was also under development for the treatment for dementia.
SanBio focuses on the research, development, manufacture, and distribution of regenerative cell medicines. The company is focusing on developing and investigating SB623, a proprietary cell-based product for the treatment of chronic traumatic brain injury, ischemic and hemorrhagic stroke; dry-age-related macular degeneration; retinitis pigmentosa; spinal cord injury; Parkinson’s and Alzheimer’s diseases. It is also developing SB618 for peripheral nerve damage; SB308 against muscle dystrophy; MSC1 for the treatment of cancer; and MSC2 targeting inflammatory diseases. The company has an operational presence in California, the US; and Singapore. SanBio is headquartered in Tokyo, Japan.
The operating loss of the company was JPY6,601.5 million in FY2022, compared to an operating loss of JPY5,801.8 million in FY2021. The net loss of the company was JPY4,677.9 million in FY2022, compared to a net loss of JPY3,385.9 million in FY2021.
For a complete picture of SB-623’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.